---
figid: PMC3837566__nihms377464f2
figlink: /pmc/articles/PMC3837566/figure/F2/
number: F2
caption: BRAF-specific inhibitors block the RAS-RAF-MEK-ERK signaling pathway in BRAFV600E
  mutant cells. However, tumor cells acquire resistance to this therapy during the
  course of treatment. Several mechanisms that involve reactivation of ERK signaling
  through amplification or mutation of proteins in the RAS-RAF-MEK-ERK pathway (i.e.
  NRAS, BRAF, CRAF and COT1) have been recently described for the development of acquired
  resistance. In addition, hyper-activation of the PI3K-Akt signaling pathway (i.e.
  through upregulation of IGF-1R or PDGFRβ) can also be involved in resistance by
  promoting survival or proliferation. BRAFV600E suppresses the LKB1 tumor suppressor
  and AMPK through the BRAF-MEK-ERK signaling cascade, and this regulation is critical
  for melanoma cell proliferation.
pmcid: PMC3837566
papertitle: 'Targeted inhibition of BRAF kinase: opportunities and challenges for
  therapeutics in melanoma.'
reftext: Rolando Pérez-Lorenzo, et al. Biosci Rep. ;32(1):10.1042/BSR20110068.
pmc_ranked_result_index: '19023'
pathway_score: 0.9341857
filename: nihms377464f2.jpg
figtitle: 'Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics
  in melanoma'
year: ''
organisms: Homo sapiens
ndex: 8b26ddff-dead-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3837566__nihms377464f2.html
  '@type': Dataset
  description: BRAF-specific inhibitors block the RAS-RAF-MEK-ERK signaling pathway
    in BRAFV600E mutant cells. However, tumor cells acquire resistance to this therapy
    during the course of treatment. Several mechanisms that involve reactivation of
    ERK signaling through amplification or mutation of proteins in the RAS-RAF-MEK-ERK
    pathway (i.e. NRAS, BRAF, CRAF and COT1) have been recently described for the
    development of acquired resistance. In addition, hyper-activation of the PI3K-Akt
    signaling pathway (i.e. through upregulation of IGF-1R or PDGFRβ) can also be
    involved in resistance by promoting survival or proliferation. BRAFV600E suppresses
    the LKB1 tumor suppressor and AMPK through the BRAF-MEK-ERK signaling cascade,
    and this regulation is critical for melanoma cell proliferation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NRAS
  - PTEN
  - MAP2K1
  - PRKAG1
  - STK11
  - MAPK1
  - MAPK3
  - CROT
  - PIK3CD
  - MAP2K2
  - PRKAB2
  - AKT3
  - PIK3CB
  - PIK3CG
  - RAF1
  - PIK3CA
  - PRKAB1
  - PRKAA2
  - PIK3R6
  - AKT1
  - PIK3R4
  - PRKAA1
  - PIK3R5
  - PIK3R3
  - PRKAG3
  - AKT2
  - PRKAG2
  - Cancer
  - Lung cancer
genes:
- word: N-RAS
  symbol: N-ras
  source: hgnc_alias_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG1
  entrez: '5571'
- word: LKB1
  symbol: LKB1
  source: hgnc_alias_symbol
  hgnc_symbol: STK11
  entrez: '6794'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: COT
  symbol: COT
  source: hgnc_alias_symbol
  hgnc_symbol: CROT
  entrez: '54677'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB2
  entrez: '5565'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB1
  entrez: '5564'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA2
  entrez: '5563'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA1
  entrez: '5562'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG3
  entrez: '53632'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG2
  entrez: '51422'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
figid_alias: PMC3837566__F2
redirect_from: /figures/PMC3837566__F2
figtype: Figure
---
